Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
All eyes on ESMO 2026 for gynecologic cancer breakthroughs. From a TROP2-directed antibody-drug conjugate to chemotherapy-free immunotherapy in endometrial cancer, this year's congress is packed with potentially practice-changing data. Clinicians and readers alike are most excited about KEYNOTE-C93, which could redefine first-line treatment for patients with mismatch repair–deficient endometrial cancer.
The 2026 ESMO Congress is shaping up to be a landmark moment for gynecologic oncology, with several high-stakes phase 3 trial readouts expected to influence future standards of care. Three abstracts are generating the most buzz — and clinicians are paying close attention.
Leading the excitement is KEYNOTE-C93, which tested pembrolizumab monotherapy vs. carboplatin/paclitaxel chemotherapy as first-line treatment in patients with dMMR advanced or recurrent endometrial cancer. Early data show pembrolizumab significantly improved progression-free survival, raising the possibility of a chemotherapy-free first-line option. Close behind is TroFuse-005, evaluating the TROP2-directed ADC sacituzumab tirumotecan vs. chemotherapy in previously treated endometrial cancer — a trial that already met its dual primary endpoints of progression-free survival and overall survival. NRG-GY020 rounds out the trio, exploring whether adding pembrolizumab to radiation can reduce recurrence in early-stage, high-intermediate–risk dMMR endometrial cancer.
Key Takeaways:
Why it matters: These trials collectively signal a rapid evolution in gynecologic cancer treatment — moving toward more targeted, less toxic regimens. The results could reshape treatment algorithms for endometrial and ovarian cancer in the near term.
